nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

01.09.2021 | Original Article

A pilot study on the melatonin treatment in patients with early septic shock: results of a single-center randomized controlled trial

verfasst von: Abbas Taher, Farnaz Shokoohmand, Elham Abdoli, Younes Mohammadi, Maryam Mehrpooya

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

We assessed the potential impact of a high dose of melatonin treatment in patients with early septic shock.

Methods

Forty patients with early septic shock were randomly allocated to the melatonin or placebo groups. Besides standard-of-care treatment, melatonin and placebo were administered at a dose of 50 mg for five consecutive nights. The efficacy outcomes were severity of organ dysfunction based on the Sequential Organ Failure Assessment (SOFA) score, the number of patients requiring mechanical ventilation and ventilator-free days, the mean required vasopressor dose and vasopressor-free days, and 28 days all-cause mortality.

Results

After 5-day treatment, the mean SOFA scores decreased 4.05 ± 4.75 score in the melatonin group and 2.25 ± 4.87 in the placebo group. On day 28, 60% of the melatonin-treated patients and 35% of the placebo-treated patients had a SOFA score below six. Thirteen cases in the placebo group and nine cases in the melatonin group required mechanical ventilation; however, there was no statistically significant difference between the groups regarding these outcomes. The melatonin-treated patients had more ventilator-free days than placebo-treated patients over the 28-day (16.90 ± 9.24 vs. 10.00 ± 10.94; p value = 0.035). The mean reduction in the required dose of vasopressor was 6.2 ± 5.12 in the melatonin-treated patients compared to 3.20 ± 3.95 in the placebo-treated patients (p value = 0.045). Vasopressor-free days in the melatonin-treated group were also significantly more than the placebo-treated group (12.75 ± 7.43 days vs. 10.15 ± 6.12 days; p value = 0.046).

Conclusions

Our pilot study supported the potential benefits of melatonin in treating septic shock. Further clinical evidence is required for expanding and confirming these findings.

Trial registration

The trial was registered at Clinicaltrials.gov (ID code: IRCT20120215009014N296). Registration date: 15/09/2019.

Physicians ACoC (1992) Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874

Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810PubMedPubMedCentralCrossRef

Galley HF (2011) Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 107(1):57–64PubMedCrossRef

Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L (2014) The role of oxidative stress during inflammatory processes. Biol Chem 395(2):203–230PubMedCrossRef

Nagar H, Piao S, Kim C-S (2018) Role of mitochondrial oxidative stress in sepsis. Acute and critical care 33(2):65PubMedPubMedCentralCrossRef

Duran-Bedolla J, de Oca-Sandoval MAM, Saldaña-Navor V et al (2014) Sepsis, mitochondrial failure and multiple organ dysfunction. Clin Invest Med E58-E69

Mantzarlis K, Tsolaki V, Zakynthinos E (2017) Role of oxidative stress and mitochondrial dysfunction in sepsis and potential therapies. Oxidative medicine and cellular longevity 2017

Pandi-Perumal SR, Trakht I, Srinivasan V et al (2008) Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 85(3):335–353PubMedCrossRef

Nowak J, Zawilska J (1998) Melatonin and its physiological and therapeutic properties. Pharm World Sci 20(1):18–27PubMedCrossRef

10.

Mahi-Birjand M, Yaghoubi S, Abdollahpour-Alitappeh M et al (2020) Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: a systematic review. Expert Opin Drug Saf 19(2):167–186PubMedCrossRef

11.

Maharaj DS, Glass BD, Daya S (2007) Melatonin: new places in therapy. Biosci Rep 27(6):299–320PubMedCrossRef

12.

Ferlazzo N, Andolina G, Cannata A et al (2020) Is Melatonin the Cornucopia of the 21st Century? Antioxidants 9(11):1088PubMedCentralCrossRef

13.

Lin G-J, Huang S-H, Chen S-J et al (2013) Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci 14(6):11742–11766PubMedPubMedCentralCrossRef

14.

Srinivasan V, Pandi-Perumal SR, Spence DW et al (2010) Melatonin in septic shock: some recent concepts. J Crit Care 25(4):656.e1-656.e6

15.

Acuña-Castroviejo D, Rahim I, Acuña-Fernández C et al (2017) Melatonin, clock genes and mitochondria in sepsis. Cell Mol Life Sci 74(21):3965–3987PubMedCrossRef

16.

Mundigler G, Delle-Karth G, Koreny M et al (2002) Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 30(3):536–540PubMedCrossRef

17.

Frisk U, Olsson J, Nylén P, Hahn RG (2004) Low melatonin excretion during mechanical ventilation in the intensive care unit. Clin Sci 107(1):47–53CrossRef

18.

Perras B, Kurowski V, Dodt C (2006) Nocturnal melatonin concentration is correlated with illness severity in patients with septic disease. Intensive Care Med 32(4):624–625PubMedCrossRef

19.

Carrillo-Vico A, Lardone PJ, Naji L et al (2005) Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 39(4):400–408PubMedCrossRef

20.

Ortiz F, García JA, Acuña-Castroviejo D et al (2014) The beneficial effects of melatonin against heart mitochondrial impairment during sepsis: Inhibition of i NOS and preservation of n NOS. J Pineal Res 56(1):71–81PubMedCrossRef

21.

Li Volti G, Musumeci T, Pignatello R et al (2012) Antioxidant potential of different melatonin-loaded nanomedicines in an experimental model of sepsis. Exp Biol Med 237(6):670–677CrossRef

22.

Wu JY, Tsou MY, Chen TH et al (2008) Therapeutic effects of melatonin on peritonitis-induced septic shock with multiple organ dysfunction syndrome in rats. J Pineal Res 45(1):106–116PubMedCrossRef

23.

Zabet MH, Mohammadi M, Ramezani M, Khalili H (2016) Effect of high-dose ascorbic acid on vasopressor’s requirement in septic shock. Journal of research in pharmacy practice 5(2):94PubMedPubMedCentralCrossRef

24.

Vincent J-L, De Mendonça A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 26(11):1793–1800PubMedCrossRef

25.

Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43(3):304–377PubMedCrossRef

26.

Patergnani S, Bouhamida E, Leo S et al (2021) Mitochondrial Oxidative Stress and “Mito-Inflammation”: Actors in the Diseases. Biomedicines 9(2):216PubMedPubMedCentralCrossRef

27.

Zhang H, Feng Y-W, Yao Y-M (2018) Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. Mil Med Res 5(1):1–11

28.

Macdonald J, Galley HF, Webster NR (2003) Oxidative stress and gene expression in sepsis. Br J Anaesth 90(2):221–232PubMedCrossRef

29.

Schulte W, Bernhagen J, Bucala R (2013) Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediat Inflamm 2013

30.

Chertoff J (2018) N-acetylcysteine’s role in sepsis and potential benefit in patients with microcirculatory derangements. J Intensive Care Med 33(2):87–96PubMedCrossRef

31.

Marik PE, Khangoora V, Rivera R et al (2017) Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study. Chest 151(6):1229–1238PubMedCrossRef

32.

Rank N, Michel C, Haertel C et al (2000) N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med 28(12):3799–3807PubMedCrossRef

33.

Macarthur H, Couri DM, Wilken GH et al (2003) Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med 31(1):237–245PubMedCrossRef

34.

Verceles AC, Silhan L, Terrin M et al (2012) Circadian rhythm disruption in severe sepsis: the effect of ambient light on urinary 6-sulfatoxymelatonin secretion. Intensive Care Med 38(5):804–810PubMedCrossRef

35.

Olofsson K, Alling C, Lundberg D, Malmros C (2004) Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand 48(6):679–684PubMedCrossRef

36.

Li C-X, Liang D-D, Xie G-H et al (2013) Altered melatonin secretion and circadian gene expression with increased proinflammatory cytokine expression in early-stage sepsis patients. Mol Med Rep 7(4):1117–1122PubMedCrossRef

37.

Escames G, León J, Macías M et al (2003) Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 17(8):1–22CrossRef

38.

Reiter RJ, Tan D-X, Mayo JC et al (2003) Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 50(4):1129–1146PubMedCrossRef

39.

Galano A, Tan DX, Reiter RJ (2013) On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J Pineal Res 54(3):245–257PubMedCrossRef

40.

Jiang-Shieh YF, Wu CH, Chien HF et al (2005) Reactive changes of interstitial glia and pinealocytes in the rat pineal gland challenged with cell wall components from gram-positive and-negative bacteria. J Pineal Res 38(1):17–26PubMedCrossRef

41.

Venegas C, García JA, Escames G et al (2012) Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 52(2):217–227PubMedCrossRef

42.

Hevia D, González-Menéndez P, Quiros-González I et al (2015) Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res 58(2):234–250PubMedCrossRef

43.

Tan D-X, Manchester LC, Qin L, Reiter RJ (2016) Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 17(12):2124PubMedCentralCrossRef

44.

Lowes D, Webster N, Murphy M, Galley H (2013) Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth 110(3):472–480PubMedPubMedCentralCrossRef

45.

Boveris A, Alvarez S, Navarro A (2002) The role of mitochondrial nitric oxide synthase in inflammation and septic shock. Free Radical Biol Med 33(9):1186–1193CrossRef

46.

López LC, Escames G, Tapias V et al (2006) Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin. Int J Biochem Cell Biol 38(2):267–278PubMedCrossRef

47.

Escames G, López LC, Ortiz F et al (2007) Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J 274(8):2135–2147PubMedCrossRef

48.

Zarezadeh M, Khorshidi M, Emami M et al (2019) Melatonin supplementation and pro-inflammatory mediators: a systematic review and meta-analysis of clinical trials. Eur J Nutr 1–11

49.

Reiter RJ, Mayo JC, Tan DX et al (2016) Melatonin as an antioxidant: under promises but over delivers. J Pineal Res 61(3):253–278PubMedCrossRef

50.

Mauriz JL, Collado PS, Veneroso C et al (2013) A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 54(1):1–14PubMedCrossRef

51.

Escames G, Acuña-Castroviejo D, López LC (2006) Tan Dx, Maldonado MD, Sánchez-Hidalgo M, León J, Reiter RJ: Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J Pharm Pharmacol 58(9):1153–1165PubMedCrossRef

52.

Rahim I, Djerdjouri B, Sayed RK et al (2017) Melatonin administration to wild‐type mice and nontreated NLRP 3 mutant mice share similar inhibition of the inflammatory response during sepsis. J Pineal Res 63(1):e12410

53.

García JA, Volt H, Venegas C et al (2015) Disruption of the NF-κB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-α and blocks the septic response in mice. FASEB J 29(9):3863–3875PubMedCrossRef

54.

An R, Zhao L, Xi C et al (2016) Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. Basic Res Cardiol 111(1):8PubMedCrossRef

55.

Şener G, Toklu H, Kapucu C et al (2005) Melatonin protects against oxidative organ injury in a rat model of sepsis. Surg Today 35(1):52–59PubMedCrossRef

56.

Volt H, García JA, Doerrier C et al (2016) Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. J Pineal Res 60(2):193–205PubMedCrossRef

57.

Hu W, Deng C, Ma Z et al (2017) Utilizing melatonin to combat bacterial infections and septic injury. Br J Pharmacol 174(9):754–768PubMedPubMedCentralCrossRef

58.

Tekbas OF, Ogur R, Korkmaz A et al (2008) Melatonin as an antibiotic: new insights into the actions of this ubiquitous molecule. J Pineal Res 44(2):222–226PubMedCrossRef

59.

Celinski K, Konturek P, Konturek S et al (2011) Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. J Physiol Pharmacol 62(5):521PubMed

60.

Wu UI, Mai FD, Sheu JN et al (2011) Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J Pineal Res 50(2):159–170PubMed

61.

Chen HH, Lin KC, Wallace CG et al (2014) Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res 57(1):16–32PubMedCrossRef

62.

Fink T, Glas M, Wolf A et al (2014) Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis. Crit Care Med 42(1):e22–e31PubMedCrossRef

63.

Shang Y, Xu S-P, Wu Y et al (2009) Melatonin reduces acute lung injury in endotoxemic rats. Chin Med J 122(12):1388–1393PubMed

64.

Sewerynek E, Melchiorri D, Reiter RJ et al (1995) Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol Environ Toxicol Pharm 293(4):327–334CrossRef

65.

Wu CC, Chiao CW, Hsiao G et al (2001) Melatonin prevents endotoxin-induced circulatory failure in rats. J Pineal Res 30(3):147–156PubMedCrossRef

66.

Annane D, Bellissant E, Cavaillon J-M (2005) Septic shock. The Lancet 365(9453):63–78CrossRef

67.

Wichmann MW, Haisken JM, Ayala A, Chaudry IH (1996) Melatonin administration following hemorrhagic shock decreases mortality from subsequent septic challenge. J Surg Res 65(2):109–114PubMedCrossRef

68.

De Paepe P, Belpaire FM, Buylaert WA (2002) Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 41(14):1135–1151PubMedCrossRef

69.

DeMuro RL, Nafziger AN, Blask DE et al (2000) The absolute bioavailability of oral melatonin. J Clin Pharmacol 40(7):781–784PubMedCrossRef

70.

Fourtillan J, Brisson A, Gobin P et al (2000) Bioavailability of melatonin in humans after day-time administration of D7 melatonin. Biopharm Drug Dispos 21(1):15–22PubMedCrossRef

71.

Galley HF, Lowes DA, Allen L et al (2014) Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res 56(4):427–438PubMedPubMedCentralCrossRef

72.

Castillo RR, Quizon GRA, Juco MJM et al (2020) Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Res 3(3):297–310CrossRef

73.

DiNicolantonio JJ, McCarty M, Barroso-Aranda J (2021) Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections. In.: Archives of Disease in childhood

74.

Gitto E, Karbownik M, Reiter RJ et al (2001) Effects of melatonin treatment in septic newborns. Pediatr Res 50(6):756–760PubMedCrossRef

75.

El Frargy M, El-Sharkawy H, Attia G (2015) Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal-Perinatal Med 8(3):227–232PubMedCrossRef

76.

El-Gendy FM, El-Hawy MA, Hassan MG (2018) Beneficial effect of melatonin in the treatment of neonatal sepsis. J Matern Fetal Neonatal Med 31(17):2299–2303PubMedCrossRef

77.

Gitto E, Reiter RJ, Cordaro SP et al (2004) Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborns: beneficial effects of melatonin. Am J Perinatol 21(04):209–216PubMedCrossRef

78.

Henderson R, Kim S, Lee E (2018) Use of melatonin as adjunctive therapy in neonatal sepsis: a systematic review and meta-analysis. Complement Ther Med 39:131–136PubMedCrossRef

79.

Aisa-Alvarez A, Soto ME, Guarner-Lans V et al (2020) Usefulness of antioxidants as adjuvant therapy for septic shock: A randomized clinical trial. Medicina 56(11):619PubMedCentralCrossRef

80.

Bourne RS, Mills GH, Minelli C (2008) Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial. Crit Care 12(2):1–9CrossRef

81.

Acuña‐Castroviejo D, Escames G, Figueira JC et al (2020) Clinical trial to test the efficacy of melatonin in COVID‐19. J Pineal Res 69(3):e12683

82.

Shneider A, Kudriavtsev A, Vakhrusheva A (2020) Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol 39(4):153–162PubMedCrossRef

83.

Ramlall V, Zucker J, Tatonetti N (2020) Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv

84.

Andersen LPH, Gögenur I, Rosenberg J, Reiter RJ (2016) The safety of melatonin in humans. Clin Drug Investig 36(3):169–175PubMedCrossRef

Titel: A pilot study on the melatonin treatment in patients with early septic shock: results of a single-center randomized controlled trial
verfasst von: Abbas Taher
Farnaz Shokoohmand
Elham Abdoli
Younes Mohammadi
Maryam Mehrpooya
Publikationsdatum: 01.09.2021
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 4/2022
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-021-02758-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

‘The medical gaze’: Foucault, anthropology and contemporary psychiatry in Ireland

Correlation of olfactory dysfunction with lung involvement and severity of COVID-19

Factors affecting the mother’s choice of infant feeding method in Poland: a cross-sectional preliminary study in Poland

Assessment of BNP and BDNF results in elective endovascular cerebral aneurysm treatment

Frequency of masked hypertension in patients with nonfunctioning adrenal incidentalomas with normal and high normal blood pressure